CO5601038A2 - Formulacion farmaceutica de iressa que comprende un derivado de celulosa hidrosoluble - Google Patents

Formulacion farmaceutica de iressa que comprende un derivado de celulosa hidrosoluble

Info

Publication number
CO5601038A2
CO5601038A2 CO04082661A CO04082661A CO5601038A2 CO 5601038 A2 CO5601038 A2 CO 5601038A2 CO 04082661 A CO04082661 A CO 04082661A CO 04082661 A CO04082661 A CO 04082661A CO 5601038 A2 CO5601038 A2 CO 5601038A2
Authority
CO
Colombia
Prior art keywords
cellulose
water
ester
soluble
ether
Prior art date
Application number
CO04082661A
Other languages
English (en)
Spanish (es)
Inventor
Paul Richard Gellert
Michael Davis Parker
De Marcel Matas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5601038(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0204392A external-priority patent/GB0204392D0/en
Priority claimed from GB0212462A external-priority patent/GB0212462D0/en
Priority claimed from GB0213267A external-priority patent/GB0213267D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5601038A2 publication Critical patent/CO5601038A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO04082661A 2002-02-26 2004-08-24 Formulacion farmaceutica de iressa que comprende un derivado de celulosa hidrosoluble CO5601038A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0204392A GB0204392D0 (en) 2002-02-26 2002-02-26 Pharmaceutical compound
GB0212462A GB0212462D0 (en) 2002-05-30 2002-05-30 Pharmaceutical compound
GB0213267A GB0213267D0 (en) 2002-06-11 2002-06-11 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
CO5601038A2 true CO5601038A2 (es) 2006-01-31

Family

ID=27767732

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04082661A CO5601038A2 (es) 2002-02-26 2004-08-24 Formulacion farmaceutica de iressa que comprende un derivado de celulosa hidrosoluble

Country Status (29)

Country Link
US (2) US20050163835A1 (enExample)
EP (1) EP1480679B1 (enExample)
JP (1) JP4544863B2 (enExample)
KR (2) KR101002374B1 (enExample)
CN (1) CN1326569C (enExample)
AR (1) AR038848A1 (enExample)
AT (1) ATE362771T1 (enExample)
AU (1) AU2003208444B2 (enExample)
BR (1) BRPI0307786B8 (enExample)
CA (1) CA2476587C (enExample)
CO (1) CO5601038A2 (enExample)
CY (1) CY1108026T1 (enExample)
DE (1) DE60313956T2 (enExample)
DK (1) DK1480679T3 (enExample)
ES (1) ES2286406T3 (enExample)
IL (2) IL163642A0 (enExample)
IS (1) IS2462B (enExample)
MX (1) MXPA04008307A (enExample)
MY (1) MY135609A (enExample)
NO (1) NO328658B1 (enExample)
NZ (1) NZ534513A (enExample)
PL (1) PL208114B1 (enExample)
PT (1) PT1480679E (enExample)
RU (1) RU2318518C2 (enExample)
SA (1) SA03240043B1 (enExample)
TW (1) TWI271193B (enExample)
UA (1) UA76325C2 (enExample)
UY (1) UY27682A1 (enExample)
WO (1) WO2003072139A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833470C (en) 2002-02-26 2016-03-29 Astrazeneca Ab Processes for preparing form 1 zd1839 polymorph
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
SI1746999T1 (sl) 2004-05-06 2012-01-31 Warner Lambert Co 4-fenilamino-kinazolin-6-il-amidi
NZ567188A (en) 2005-09-12 2011-04-29 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2008050209A1 (en) 2006-10-27 2008-05-02 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
CA2686964A1 (en) * 2007-06-06 2008-12-11 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
BRPI1015941A2 (pt) * 2009-07-02 2016-04-19 Wyeth Llc formulações de comprimido de 3-cianoquinolina e uso das mesmas.
BR112012014499A2 (pt) * 2009-12-22 2016-08-16 Abbott Lab cápsula de abt-263
JP4574742B1 (ja) * 2010-04-08 2010-11-04 有限会社ミールジャパン プロポリス組成物
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
ES2699205T3 (es) 2010-10-29 2019-02-07 Abbvie Inc Dispersiones sólidas que contienen un agente que induce la apoptosis
AU2011332043C1 (en) 2010-11-23 2016-11-10 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
WO2012071340A1 (en) 2010-11-23 2012-05-31 Metamagnetics Inc. Antenna module having reduced size, high gain, and increased power efficiency
NZ708508A (en) 2010-11-23 2016-06-24 Abbvie Bahamas Ltd Methods of treatment using selective bcl-2 inhibitors
CN102631347B (zh) * 2012-05-03 2014-06-25 石药集团中奇制药技术（石家庄）有限公司 一种吉非替尼药物组合物及其制备方法
CN113372358B (zh) 2012-09-28 2024-05-14 武田药品工业株式会社 噻吩并嘧啶衍生物的制备方法
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101332829B1 (ko) * 2013-05-31 2013-11-27 재단법인 통합의료진흥원 보중익기탕을 포함하는 폐암 치료용 조성물
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
KR101721831B1 (ko) * 2014-11-06 2017-03-31 주식회사 종근당 로베글리타존을 함유하는 경구 투여용 약제학적 조성물
WO2016096999A1 (en) * 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising gefifinib
SI4233847T1 (sl) * 2015-02-26 2025-02-28 Takeda Pharmaceutical Company Limited Tableta, ki vsebuje derivat metoksiuree in delce manitola
KR101739731B1 (ko) * 2015-12-31 2017-05-25 환인제약 주식회사 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물
JP6739289B2 (ja) * 2016-08-25 2020-08-12 日本化薬株式会社 ゲフィチニブを有効成分とする医薬錠剤の製造方法
AU2017334035B2 (en) 2016-09-30 2022-11-24 Sumitomo Pharma Switzerland Gmbh Treatment of prostate cancer
CN108096251B (zh) * 2016-11-24 2021-11-16 江苏恒瑞医药股份有限公司 一种吉非替尼药物组合物及其制备方法
CN107007562B (zh) * 2017-02-16 2020-10-27 南京优科制药有限公司 一种吉非替尼片剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US4178376A (en) * 1977-01-21 1979-12-11 Interx Research Corporation Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
WO1995006462A1 (en) * 1993-08-30 1995-03-09 Warner-Lambert Company Tablet coating based on a melt-spun mixture of a saccharide and apolymer
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB2306885B (en) * 1995-11-08 1999-07-14 Reckitt & Colmann Prod Ltd Supersaturated Pharmaceutical Compositions
JP4713698B2 (ja) * 1997-03-05 2011-06-29 スージェン， インク． 疎水性薬剤の処方
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
DE60028754T2 (de) * 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
CA2833470C (en) * 2002-02-26 2016-03-29 Astrazeneca Ab Processes for preparing form 1 zd1839 polymorph
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물

Also Published As

Publication number Publication date
CN1638805A (zh) 2005-07-13
IS7420A (is) 2004-08-24
US20090186890A1 (en) 2009-07-23
KR20100090726A (ko) 2010-08-16
MY135609A (en) 2008-05-30
DE60313956D1 (de) 2007-07-05
UY27682A1 (es) 2003-10-31
IL163642A (en) 2007-07-24
TWI271193B (en) 2007-01-21
NZ534513A (en) 2007-04-27
WO2003072139A1 (en) 2003-09-04
TW200304379A (en) 2003-10-01
AR038848A1 (es) 2005-01-26
RU2004129280A (ru) 2005-06-10
CY1108026T1 (el) 2013-09-04
KR20040088524A (ko) 2004-10-16
ATE362771T1 (de) 2007-06-15
CN1326569C (zh) 2007-07-18
KR101002374B1 (ko) 2010-12-17
CA2476587C (en) 2010-05-04
US20050163835A1 (en) 2005-07-28
UA76325C2 (uk) 2006-07-17
PL208114B1 (pl) 2011-03-31
DK1480679T3 (da) 2007-09-03
ES2286406T3 (es) 2007-12-01
BRPI0307786B8 (pt) 2021-05-25
BR0307786A (pt) 2004-12-07
DE60313956T2 (de) 2008-05-15
AU2003208444B2 (en) 2006-10-26
MXPA04008307A (es) 2004-11-26
AU2003208444A1 (en) 2003-09-09
SA03240043B1 (ar) 2007-05-06
PT1480679E (pt) 2007-07-18
HK1070585A1 (en) 2005-06-24
NO328658B1 (no) 2010-04-19
JP2005523293A (ja) 2005-08-04
RU2318518C2 (ru) 2008-03-10
EP1480679B1 (en) 2007-05-23
BRPI0307786B1 (pt) 2018-03-13
JP4544863B2 (ja) 2010-09-15
CA2476587A1 (en) 2003-09-04
PL372215A1 (en) 2005-07-11
EP1480679A1 (en) 2004-12-01
IS2462B (is) 2008-11-15
NO20043866L (no) 2004-09-15
IL163642A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
CO5601038A2 (es) Formulacion farmaceutica de iressa que comprende un derivado de celulosa hidrosoluble
CR9767A (es) COMPOSICION QUE COMPRENDE UN INHIBIDOR DE LA ABSORCION DEL COLESTEROL UN INHIBIDOR DE LA HMG-COA Y UN AGENTE ESTABILIZADOR Solicitud divisional 7658
ATE399174T1 (de) Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen
PE20100363A1 (es) Composiciones que comprenden nucleosidos
ATE284861T1 (de) N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden
DK0873351T3 (da) Steroidnitrit/nitratesterderivater anvendelige som antiinflammatoriske lægemidler
AR015157A1 (es) DERIVADOS DEL ÁCIDO 5-ALQUIL-2-ARILAMINOFENILÁCETICO, COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE, SU USO EN LA MANUFACTURA DE UN MEDICAMENTO Y MÉTODO DE PREPARACIoN DEL MISMO
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
ATE241990T1 (de) 3-beta-hydroxylierte natürliche steroidderivate enthaltende arzneimittelzusammensetzungen und ihre verwendung
ES2154270T3 (es) Nuevos derivados del imidazol, su preparacion y sus aplicaciones terapeuticas.
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
ES2165833T1 (es) Composicion farmaceutica revestida enterica y procedimiento de fabricacion.
ATE372334T1 (de) Phenylpyrazolderivate als seh-inhibitoren
NO20051688L (no) Farmasoytiske blandinger som har en modifisert baerer
YU49443B (sh) Derivati benzimidazola, postupci za njihovo pripremanje i primena tih derivata u medicinskoj terapiji, naročito za lečenje ili sprečavanje virusnih infekcija
RU2008136198A (ru) Полимерные композиции ингибиторов сетр
PE20020994A1 (es) Composicion antifungal con aumentada biodisponibilidad
DE60037726D1 (de) Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
ES2188426A1 (es) Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
NO20013966D0 (no) Kombinasjoner for behandling av sykdommer som involverer angiogenese
IL158899A0 (en) Pharmaceutical compositions for inhibiting angiogenesis containing oleuropein and derivatives thereof
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
ITRM20020016A0 (it) Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
MXPA02012160A (es) Composiciones medicinales las cuales contienen derivados de propenona.

Legal Events

Date Code Title Description
FC Application refused